Equitable treatment for HIV/AIDS clinical trial participants: a focus group study of patients, clinician researchers, and administrators in western Kenya

Objectives: To describe the concerns and priorities of key stakeholders in a developing country regarding ethical obligations held by researchers and perceptions of equity or “what is fair” for study participants in an HIV/AIDS clinical drug trial. Design: Qualitative study with focus groups. Settin...

Full description

Saved in:  
Bibliographic Details
Authors: Shaffer, D. N. (Author) ; Yebei, V. N. (Author) ; Ballidawa, J. B. (Author) ; Sidle, J. E. (Author) ; Greene, J. Y. (Author) ; Meslin, E. M. (Author) ; Kimaiyo, S. J. N. (Author) ; Tierney, W. M. (Author)
Format: Electronic Article
Language:English
Check availability: HBZ Gateway
Journals Online & Print:
Drawer...
Fernleihe:Fernleihe für die Fachinformationsdienste
Published: BMJ Publ. 2006
In: Journal of medical ethics
Year: 2006, Volume: 32, Issue: 1, Pages: 55-60
Online Access: Volltext (JSTOR)
Volltext (kostenfrei)
Volltext (kostenfrei)

MARC

LEADER 00000naa a22000002 4500
001 181612995X
003 DE-627
005 20220908053420.0
007 cr uuu---uuuuu
008 220908s2006 xx |||||o 00| ||eng c
024 7 |a 10.1136/jme.2004.011106  |2 doi 
035 |a (DE-627)181612995X 
035 |a (DE-599)KXP181612995X 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 1  |2 ssgn 
100 1 |a Shaffer, D. N.  |e VerfasserIn  |4 aut 
245 1 0 |a Equitable treatment for HIV/AIDS clinical trial participants: a focus group study of patients, clinician researchers, and administrators in western Kenya 
264 1 |c 2006 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
520 |a Objectives: To describe the concerns and priorities of key stakeholders in a developing country regarding ethical obligations held by researchers and perceptions of equity or “what is fair” for study participants in an HIV/AIDS clinical drug trial. Design: Qualitative study with focus groups. Setting: Teaching and referral hospital and rural health centre in western Kenya. Participants: Potential HIV/AIDS clinical trial participants, clinician researchers, and administrators. Results: Eighty nine individuals participated in a total of 11 focus groups over a four month period. The desire for continued drug therapy, most often life long, following an HIV/AIDS clinical trial was the most common priority expressed in all focus groups. Patients with and without HIV/AIDS also thought subsidisation of drug therapies and education were critical forms of compensation for clinical trial participation. Financial incentives were considered important primarily for purchasing drug therapy as well as obtaining food. Patients noted a concern for the potential mismanagement of any money offered. Clinician researchers and administrators felt strongly that researchers have a moral obligation to participants following a trial to provide continued drug therapy, adverse event monitoring, and primary care. Finally, clinician researchers and administrators stressed the need for thorough informed consent to avoid coercion of study participants. Conclusions: Kenyan patients, clinician researchers, and administrators believe that it would be unfair to stop antiretroviral therapy following an HIV/AIDS clinical trial and that researchers have a long term obligation to participants. 
601 |a Patient 
601 |a Administration 
601 |a Western 
700 1 |a Yebei, V. N.  |e VerfasserIn  |4 aut 
700 1 |a Ballidawa, J. B.  |e VerfasserIn  |4 aut 
700 1 |a Sidle, J. E.  |e VerfasserIn  |4 aut 
700 1 |a Greene, J. Y.  |e VerfasserIn  |4 aut 
700 1 |a Meslin, E. M.  |e VerfasserIn  |4 aut 
700 1 |a Kimaiyo, S. J. N.  |e VerfasserIn  |4 aut 
700 1 |a Tierney, W. M.  |e VerfasserIn  |4 aut 
773 0 8 |i Enthalten in  |t Journal of medical ethics  |d London : BMJ Publ., 1975  |g 32(2006), 1, Seite 55-60  |h Online-Ressource  |w (DE-627)323607802  |w (DE-600)2026397-1  |w (DE-576)260773972  |x 1473-4257  |7 nnns 
773 1 8 |g volume:32  |g year:2006  |g number:1  |g pages:55-60 
856 |3 Volltext  |u http://www.jstor.org/stable/27719558  |x JSTOR 
856 |u https://jme.bmj.com/content/medethics/32/1/55.full.pdf  |x unpaywall  |z Vermutlich kostenfreier Zugang  |h publisher [open (via free pdf)] 
856 4 0 |u https://doi.org/10.1136/jme.2004.011106  |x Resolving-System  |z kostenfrei  |3 Volltext 
856 4 0 |u http://jme.bmj.com/content/32/1/55.abstract  |x Verlag  |z kostenfrei  |3 Volltext 
935 |a mteo 
951 |a AR 
ELC |a 1 
ITA |a 1  |t 1 
LOK |0 000 xxxxxcx a22 zn 4500 
LOK |0 001 4185583818 
LOK |0 003 DE-627 
LOK |0 004 181612995X 
LOK |0 005 20220908053420 
LOK |0 008 220908||||||||||||||||ger||||||| 
LOK |0 035   |a (DE-Tue135)IxTheo#2022-08-02#EAF065C210E3F352ABBF0DE5D4AC72B008B70DAC 
LOK |0 040   |a DE-Tue135  |c DE-627  |d DE-Tue135 
LOK |0 092   |o n 
LOK |0 852   |a DE-Tue135 
LOK |0 852 1  |9 00 
LOK |0 866   |x JSTOR#http://www.jstor.org/stable/27719558 
LOK |0 935   |a ixzs  |a ixrk  |a zota 
OAS |a 1 
ORI |a SA-MARC-ixtheoa001.raw